IPO Syndax Pharmaceuticals, Inc (SNDX) is a late-stage biopharmaceutical company focused on the development and commercialization of their lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment